Blog | Veristat Insightful Perspectives

Contact Veristat Now


Request A Proposal

Contact Us

Understanding When to Submit an IND Application to the FDA

An Interview with Kevin Hennegan, Senior Regulatory Strategist, Veristat

Read More

Evolving Risk-Based Monitoring to Improve Clinical Studies

An Interview with Dunya Botetzayas, RN, Senior Director of Clinical Monitoring at Veristat

Read More

5 Best Practices for Making Virtual Teams Work

At Veristat our need to manage and work in virtual environments continues to increase. With six offices globally and nearly 300 employees, we are building teams with members spread out in different physical locations. Our geographically dispersed teams continue to grow with our increasing remote employee population; In fact remote workers are our largest growing population with nearly 30 % of our employees working from their home offices.

Read More

Team Veristat Raised over $50K To Support Rare Cancer Research

Our Challenge:   Join the Battle to Beat Rare Cancers

Our Impact:   $150K Raised to Support Rare Cancer Research

For a fifth consecutive year, Team Veristat accepted this challenge in the 2019 Boston #cycleforsurvival event!   We exceeded our goal of raising $50,000 to support rare cancer research.

Read More

More Seats at the Table | The Growth of Female Leadership in Healthcare

As a Talent Acquisition Consultant for Veristat, I receive many cover letters and resumes from candidates each day. I am often blown away by the experience, knowledge, and expertise of these individuals and always hope to match their skill sets to one of our current openings. 

Read More

What  to Know Before Considering an Adaptive Design Clinical Trial

By John Balser, PhD, President, Mark Chang, PhD, Senior Vice President, and Robin Bliss, PhD, Director

The Food and Drug Administration (FDA) has started encouraging the use of adaptive designs for clinical studies. In essence, adaptive designs allow prospectively planned modifications to a clinical trial based on interim data, provided scientific validity (the ability to draw sound inferences) and data integrity (credibility and reproducibility) are preserved. 

Read More

Flexibility is the Key to Data Acquisition for Rare Disease Trials

Understanding Why Creative Data Collection Solutions Are Necessary

Read More

Delivering Smarter, Faster & Patient-Centric  Clinical Trials with Integrated Clinical Technologies

A Recap of the New York Medidata NEXT Event: Where Science Meets Technology Meets the Future

 

Kathleen Boruchowski, Associate Director of Data Management, attended the Medidata NEXTconference in New York City on November 8-10. The conference, which has many global locations throughout the year, offered Medidata’s customers a front row seat to learn how data, insights, and technology are transforming the clinical trials industry and ultimately accelerating the hope for patients desperately seeking new treatment options.

Read More

Competing Risk Analysis in Clinical Trials | A Practical Example

In pharmaceutical clinical trials, considering competing risk analyses is highly important. Competing risks are events that may occur and prevent the evaluation of a specific primary endpoint, in turn biasing risk estimations or drug efficacy. 

Read More

Veristat Launches New eTMF System

To Improve Real-Time Visibility of Clinical Trial Documentation and Inspection-Readiness

Veristat has completed the validation and configuration of Master Control’s eTMF system, which is now implemented and available for Veristat managed clinical trials. 

Read More